Phenotypic and genotypic variations in Candida albicans isolates from Romanian patients

Open access

Abstract

Background: During the last two decades a major increase in the proportion of severe fungal infections has been noted due to the excessive use of broad-spectrum antibiotics, catheters, and a growing number of immunocompromised patients.

Objectives: This is the first investigation providing complete data regarding the phenotypic and genotypic profiles of Candida albicans (C. albicans) isolates in Romanian patients.

Methods: We investigated 301 isolates in terms of genotype determination (G), resistogram (R), phospholipase activity (Pl), haemolysis (Hl), proteinase activity (Pt), and biofilm formation (BF).

Results: The analyzed isolates of C. albicans showed low values for Pt (61.73%), Hl (95.49%), and BF (60.71%), and did not present any Pl activity (92.23%). More than half of the investigated samples were genotype A with 450 bp (52.92%) and the majority (86.19%) were resistant to sodium selenite (A), boric acid (B), sodium periodate (D) and silver nitrate (E), but sensitive to cetrimide (-). One-way ANOVA analysis revealed significant effects of the infection site on biofilm formation (p = 0.0137) and no significant correlation was found between the genotype (A, B, C) and the infection site (p =0.449).

Conclusions: Based on the obtained results it can be concluded that C. albicans isolates in Romanian patients exhibit different genotypic and phenotypic patterns, and no significant correlations between genotype and infection site could be observed.

1. Wong SSW, Samaranayake LP, Seneviratne CJ. In pursuit of the ideal antifungal agent for Candida infections: high-throughput screening of small molecules. Drug Discov Today. 2014 Nov;19(11):1721-0. DOI: 10.1016/j.drudis.2014.06.009

2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007 Jan;20(1):133-3. DOI: 10.1128/CMR.00029-06

3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36(1):1-53. DOI: 10.3109/10408410903241444

4. Kabir MA, Hussain MA, Ahmad Z. Candida albicans: a model organism for studying fungal pathogens. ISRN Microbiol. 2012 Sep 29;2012:538694.

5. Dixon DM, McNeil MM, Cohen ML, Gellin BG, La Montagne JR. Fungal infections: a growing threat. Public Health Rep. 1996 May-Jun;111(3):226–5.

6. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis. 2002 Dec;15(6):569-4. DOI: 10.1097/00001432-200212000-00003

7. Ruhnke M, Maschmeyer G. Management of mycoses in patients with hematologic disease and cancer—review of the literature. Eur J Med Res. 2002 May 31;7(5):227-5.

8. Sanita PV, de Oliveira Mima EG, Pavarina AC, Jorge JH, Machado AL, Vergani CE. Susceptibility profile of a Brazilian yeast stock collection of Candida species isolated from subjects with Candida-associated denture stomatitis with or without diabetes. Oral Surg Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Nov;116(5):562-9. DOI: 10.1016/j.oooo.2013.07.002

9. Gow NAR, van de Veardonk FL, Brown AJP, Netea MG. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol. 2011 Dec 12;10(2):112-2. DOI: 10.1038/nrmicro2711

10. Perlin DS. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs. 2014 Sep;74(14):1573-5. DOI: 10.1007/s40265-014-0286-5

11. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol. 2002 Feb;40(2):341-0. DOI: 10.1128/JCM.40.2.341-350.2002

12. Vergani CE, Sanitá PV, Mima EGO, Pavarina AC, Machado AL. Oral candidiasis: Conventional and alternative treatment options. In: Contreras F and Fuentes P (eds) Candidiasis: Epidemiology, Symptoms and Treatment Options, 1st edn. Nova Medical, New York, pp 85–115.

13. Molero G, Díez-Orejas R, Navarro-García F, Monteoliva L, Pla J, Gil C, et al. Candida albicans: genetics, dimorphism and pathogenicity. Int Microbiol. 1998 Jun;1(2):95-106.

14. Poradzka A, Jasik M, Karnafel W, Fiedor P. Clinical aspects of fungal infections in diabetes. Acta Pol Pharm. 2013 Jul-Aug;70(4):587-6.

15. Romeo O, Criseo G. Candida africana and its closest relatives. Mycoses 2011 Nov;54(6):475-6. DOI: 10.1111/j.1439-0507.2010.01939.x

16. McCullough MJ, Clemons KV, Stevens DA. Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol. 1999 Feb;37(2):417-1.

17. Li W, Yu D, Gao S, Lin J, Chen Z, Zhao W. Role of Candida albicans secreted aspartyl proteinases (Saps) in severe early childhood caries. Int J Mol Sci. 2014 Jun 13;15(6):10766-9. DOI: 10.3390/ijms150610766

18. Tamura M, Watanabe K, Mikami J, Yazawa K, Nishimura K. Molecular characterization of new chemical isolates of Candida albicans and Candida dubliniensis in Japan. Analysis reveals a new genotype of Candida albicans with Group I Intron. J Clin Microbiol. 2001 Dec;39(12):4309-5. DOI: 10.1128/JCM.39.12.4309-4315.2001

19. She XD, Wang XJ, Fu MH, Shen YN, Liu WD. Genotype comparisons of strains of Candida albicans from patients with cutaneous candidiasis and vaginal candidiasis. Chin Med J (Engl). 2008 Aug 5;121(15):1450-5.

20. McCreight MC, Warnock DW. Enhanced differentiation of isolates of Candida albicans using a modified rezistogram method. Mykosen 1982 Nov;25(11):589-8. DOI: 10.1111/j.1439-0507.1982.tb01926.x

21. Nakamura K, Ito-Kuwa S, Nakamura Y, Aoki S, Vidotto V, Sinicco A. Resistogram typing of the oral Candida albicans isolates from normal subjects in three successive trials. Rev Iberoam Micol. 1998 Mar;15(1):19-1.

22. Prince MF, Wilkinson ID, Gentry LO. Plate methods for detection of phospholipase activity in Candida albicans. Sabouraudia. 1982 Mar;20(1):7-14. DOI: 10.1080/00362178285380031

23. Rasband WS. Image Processing and Analysis in Java (Image J), U.S. National Institutes of Health, Bethesda, Maryland USA, http://imagej.nih.gov/ij. Accessed 17 November 2017.

24. Manns JM, Mosser DM, Buckley HR. Production of a haemolytic factor by Candida albicans. Infect Immun. 1994 Nov;62(11):5154–6.

25. Luo G, Samarannayake LP, You JYY. Candida species exhibit differential in vitro haemolytic activities. J Clin Microbiol. 2001 Aug;39(8):2971–4. DOI: 10.1128/JCM.39.8.2971-2974.2001

26. Barros LM, Boriollo MP, Alves AC, Klein MI, Gonçalves RB, Höfling JF. Genetic diversity and exo-enzyme activity of Candida albicans and Candida dubliniensis isolated from the oral cavity of Brazilian periodontal patients. Arch Oral Biol. 2008 Dec;53(12):1172-8. DOI: 10.1016/j.archoralbio.2008.06.003

27. Pierce CG, Uppuluri P, Tristan AR, Wormley FL Jr, Mowat E, Ramage G, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc. 2008;3(9):1494-0. DOI: 10.1038/nprot.2008.141

28. Al-Karaawi ZM, Manfredi M, Waugh ACW, McCullough MJ, Jorge J, Scully C, et al. Characterization of Candida spp. isolated from the oral cavities of patients from diverse clinical settings. Oral Microbiol Immunol. 2002 Feb;17(1):44-9. DOI: 10.1046/j.0902-0055.2001.00081.x

29. Sugita T, Kurosaka S, Yajitate M, Sato H, Nishikawa A. Extracellular proteinase and phospholipase activity of three genotypic strains of a human pathogenic yeast Candida albicans. Microbiol Immunol. 2002;46(12):881-3. DOI: 10.1111/j.1348-0421.2002.tb02776.x

30. Willis AM, Coulter WA, Fulton CR, Hayes JR, Bell PM, Lamey PJ. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Mar;91(3):317-1. DOI: 10.1067/moe.2001.112155

31. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev. 2000 Jan;13(1):122-3. DOI: 10.1128/CMR.13.1.122-143.2000

32. Hannula J, Saarela M, Dogan B, Paatsama J, Koukila-Kähkölä P, Pirinen S, et al. Comparison of virulence factors of oral Candida dubliniensis and Candida albicans isolates in healthy people and patients with chronic candidosis. Oral Microbiol Immunol. 2000 Aug;15(4):238-4. DOI: 10.1034/j.1399-302x.2000.150405.x

33. Vidotto V, Koga-Ito CY, Milano R, Fianchino B, Poton J. Correlation between germ tube production, phospholipase activity and serotype distribuition in Candida albicans. Rev Iberoam Micol. 1999 Dec;16(4):208-0.

34. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev. 2003 Sep;67(3):400-8. DOI: 10.1128/MMBR.67.3.400-428.2003

35. Watanabe T, Takano M, Murakami M, Tanaka H, Matsuhisa A, Nakao N, et al. Characterization of a haemolytic factor from Candida albicans. Microbiology. 1999 Mar;145(Pt 3):689-4. DOI: 10.1099/13500872-145-3-689

36. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. Crit Rev Microbiol. 2009;35(4):340-5. DOI: 10.3109/10408410903241436

37. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 2004 Apr;17(2):255–7. DOI: 10.1128/CMR.17.2.255-267.2004

38. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int J Microbiol. 2012;2012:528521. DOI: 10.1155/2012/528521

39. Sherry L, Rajendran R., Lappin D.F, Borghi E, Perdoni F, Falleni M, et al. Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiol. 2014;14:182-6. DOI: 10.1186/1471-2180-14-182

40. Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, Lopez-Ribot JL (2013) Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol. 2013 Oct;13(5):726–0. DOI: 10.1016/j.coph.2013.08.008

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 20 20 20
PDF Downloads 9 9 9